Recursion (RXRX) Gets FDA Alignment on REC-4881 Phase 3 Design
Recursion (RXRX) announced alignment with the FDA on the Phase 3 design for REC-4881, with trial initiation planned for the second half of 2027. The study aims to enroll around 200 patients, following Phase 2 results.
How this was made

The 30-second read
Why it matters
FDA alignment signals regulatory confidence, but the trial start is over a year away, so price reaction may be modest.
Market read
The announcement provides a new data point for investors tracking biotech pipeline milestones.
What to watch
Potential competition in the same indication and the need for additional funding before trial start.
Background
Recursion is a clinical‑stage biotech focused on AI‑driven drug discovery. The REC‑4881 program targets a specific oncology indication.
Ticker impact
Recursion announced FDA alignment on the Phase 3 design for its REC-4881 oncology trial, a new development milestone.
potential upside as investors price in reduced risk and future data milestones
While the news is material, the trial will not start until H2 2027, limiting immediate price impact.
Market effects
Adds confidence to the broader biotech sector's pipeline progression outlook.
Minimal regional effect; primarily U.S. biotech investors.
Limited global relevance beyond biotech investors.
Counterpoint
The long timeline to data may dilute the news impact; investors could remain cautious.
Key entities
- CompanyRecursion Pharmaceuticals
US‑listed biotech (RXRX) developing REC‑4881.



